Risultati della ricerca - Michael Hulse
- Mostra 1 - 7 risultati su 7
-
1
-
2
-
3
The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity di Sarah M. Morgan, Hideki Tanizawa, Lisa Beatrice Caruso, Michael Hulse, Andrew V. Kossenkov, Jozef Madžo, Kelsey Keith, Yinfei Tan, Sarah C. Boyle, Paul M. Lieberman, Italo Tempera
Pubblicazione 2022Artigo -
4
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies di Jack Carter, Michael Hulse, Monisha Sivakumar, Jessica Burtell, Venkat Thodima, Min Wang, Anjana Agarwal, Komali Vykuntam, Jacob Spruance, Neha Bhagwat, Joseph Rager, Bruce Ruggeri, Peggy Scherle, Koichi Ito
Pubblicazione 2023Artigo -
5
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer di Katelyn D. Miller, Seamus O’Connor, Katherine Pniewski, Toshitha Kannan, Reyes Acosta, Gauri Mirji, Sara B. Papp, Michael Hulse, Dzmitry Mukha, Sabina I. Hlavaty, Kelsey Salcido, Fabrizio Bertolazzi, Y. V. V. Srikanth, Steven Zhao, Kathryn E. Wellen, Rahul Shinde, Daniel T. Claiborne, Andrew V. Kossenkov, Joseph M. Salvino, Zachary T. Schug
Pubblicazione 2023Artigo -
6
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and<i>ESR1</i>-Mutant Breast Tumors in Preclinical Models di Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena Callis, Jon Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J. Feron, Galith Karoutchi, Philip A. MacFaul, Tom Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth M. Davies, Graeme E. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, C Sadler, Graham H.P. Richmond, Brendon Ladd, Ermira Pazolli, Anne Marie Mazzola, Celina M. D’Cruz, Chris De Savi
Pubblicazione 2016Artigo -
7
<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors di Silvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, Konstantin Golovine, Katherine Sullivan-Reed, Wangisa M.B. Dunuwille, Joseph Nacson, Michael Hulse, Kelsey Keith, Jozef Madžo, Lisa Beatrice Caruso, Zachary Gazze, Zhaorui Lian, Antonella Padella, Kumaraswamy Naidu Chitrala, Boris Bartholdy, Ksenia Matławska-Wasowska, Daniela Di Marcantonio, Giorgia Simonetti, Georg Greiner, Stephen M. Sykes, Peter Valent, Elisabeth Paietta, Martin S. Tallman, Hugo F. Fernández, Mark R. Litzow, Mark D. Minden, Jian Huang, Giovanni Martinelli, George S. Vassiliou, Italo Tempera, Katarzyna Piwocka, Neil Johnson, Grant A. Challen, Tomasz Skórski
Pubblicazione 2021Artigo
Strumenti per la ricerca:
Soggetti correlati
Biology
Gene
Cancer research
Genetics
Poly ADP ribose polymerase
Polymerase
Cancer
Gene expression
PARP1
Breast cancer
CTCF
Cell biology
Chromatin
DNA
DNA damage
DNA repair
Enhancer
Internal medicine
Medicine
PARP inhibitor
Synthetic lethality
Virology
ATP synthase
Antagonist
Biochemistry
Cell
Cell mediated immunity
Cell membrane
ChIA-PET
Chemotherapy